European journal of cancer (Oxford, England : 1990)HumansCarcinomaNon-Small-Cell LungNivolumabMale
Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung).
Kristof Cuppens, Marcel Wiesweg, Paul Baas, Brigitte Maes, Bert Du Pont, Till Ploenes, Dirk Theegarten, Michel Vanbockrijck, Clemens Aigner, Koen Hartemink, Fabian Doerr, Servet Bölükbas, Karin Pat, Martin Schuler
Published: 202610.1016/j.ejca.2025.116165
Abstract
BACKGROUND: Preoperative immunotherapy targeting PD-1/-L1 with chemotherapy induces histopathological responses and improves survival in patients with resectable non-small cell lung cancer (NSCLC). NEOpredict-Lung (NCT04205552) established the feasib…
Preview only. Read the full abstract at the source